Destiny Pharma, a leading clinical stage pharmaceutical company focused on developing antibacterial medicines, is pleased to welcome and applaud the final report and recommendations of the UK Review of Antimicrobial Resistance (AMR Review) chaired by Lord O’Neill.
In July 2014, the UK Government commissioned the Review on Antimicrobial Resistance in collaboration with the Wellcome Trust. The Review is independent and engages widely with international stakeholders to understand and propose solutions to the problem of antimicrobial resistance, from an economic and social perspective and outlines 10 areas where the world needs to take action to tackle AMR. Many of these measures focus on reduction of antibiotic resistant infections, incentivising industry to develop much needed new drugs and infection prevention approaches.
Dr Bill Love, CEO of Destiny Pharma, commented: “Antibiotic resistance is a recognized global threat. If not addressed, it is predicted to have a greater impact than cancer, a $100 trillion annual global cost and is the harbinger of the end of modern medicine as we know it. We welcome the final report and recommendations of the Review of Antimicrobial Resistance. Addressing the lack of development of new antibiotics, and the urgent need for novel antibacterial drugs — ideally ones which counter bacterial drug resistance — is of paramount importance.”
“There has been an absence of Big Pharma in the development of antibiotics: smaller, independent companies such as Destiny Pharma have driven innovation in recent years and have products close to market. The proposal for Market Entry Rewards as outlined in the O’Neill report potentially rewarding companies with a $1 billion payment upon new drug approval, would be a shot in the arm for developing much needed new drugs. The report also recommends a Play or Pay levy on Big Pharma to help fund new products, which is offset if they already develop drugs in this area. Adoption and implementation of the report recommendations is estimated to cost $4 billion a year, a fraction (0.05%) of the G20’s spend on healthcare and a small price to pay to address this global crisis. Political consensus will be crucial in delivering these recommendations and we look forward to the discussions at the forthcoming global forums, including the G7, G20 and for the first time AMR is on the high level agenda of United Nations General Assembly meeting,” he added.
One of Destiny Pharma’s XF drug product developments is an antibacterial drug that tackles the prevention of post-surgical bacterial infection, including antibiotic resistant bacteria — a major cause of hospital infection. The lead drug candidate, XF-73, has completed four clinical studies in the UK and shown to reduce the number of bacteria rapidly, with a US clinical trial to be reported shortly. In laboratory tests XF-73 has been shown not to succumb to bacterial resistance — unlike traditional antibiotics. XF-73 was granted Qualifying Infectious Disease Product (QIDP) status in October 2015 by the FDA for a new US indication for the “Prevention of post-surgical Staphylococcal infection.”
Dr Bill Love added: “At Destiny Pharma, our innovative drug development has already produced the revolutionary XF drug series. Evidence shows that the likelihood of bacterial resistance developing to these drugs is remote, offering a totally new means to prevent and treat certain bacterial infections. The stimulus of the AMR Report recommendations will assist us to achieve our goal of a new range of novel antimicrobial drug products.”